Enhanced technology environment simplifies implementation and utilization to make electronic Clinical Outcome Assessments (eCOA) accessible for every trial
Philadelphia, PA – ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced the launch of its refreshed eCOA technology environment, which dramatically simplifies the implementation and management of trials that require collection of Clinical Outcomes Assessments.
Designed to support simple to the most complex studies, ERT’s eCOA environment collects patient data anywhere, anytime, and in any language, and can be provisioned across mobile devices, web browers and patients’ own devices (known as BYOD or bring your own device). On-device calculations and medical device integrations enable real-time access to operational and clinical data, so sponsors see how their study is performing, and ensure patient safety.
“We are shattering the commonly-held misconception that a paper-based solution is easier or less expensive than technology,” said Ron Sullivan, Executive Vice President, eCOA at ERT. “ERT’s eCOA environment has all the quality, consistency and administrative benefits inherent with an electronic solution, and now is easy to implement and even easier to manage.”
ERT’s eCOA environment provides uniform data collection with more efficient study change management and mitigates the need for manual data reconciliation. Formerly customized features are now included as standard, and pre-configured study components are widely available. Additionally, complimentary protocol review by ERT’s expansive team of patient reported outcomes (PRO)/eCOA Clinical Scientists ensures fit-for-purpose design on every study.
“Now we can enable sponsors to focus on clinical research – not the minutiae of data collection and assimilation,” continued Sullivan. “Trial leaders can reduce uncertainty and have confidence in their collected data, while keeping studies on time and on budget.”
For additional information on ERT’s enhanced eCOA solution, visit ert.com/eCOA.
About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With more than 40 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. Over the past four years, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs, and CROs have relied on ERT solutions in 9,500+ studies spanning three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence. For more information, go to ert.com or follow us on LinkedIn, Twitter, and Facebook.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.